U.S. Markets close in 4 hrs 20 mins

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
148.07+2.21 (+1.52%)
As of 11:39AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close145.85
Bid147.27 x 900
Ask147.56 x 800
Day's Range144.21 - 148.35
52 Week Range117.58 - 212.00
Avg. Volume904,137
Market Cap17.709B
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-7.13
Earnings DateApr 27, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est208.20

    Alnylam's 5th Drug Launches in July, Disrupting Commercial Landscape

    A little competition can greatly benefit patients. Shareholders may have a more difficult path to navigate.

  • American City Business Journals

    Peninsula company raises $120M to build new vehicles for mRNA drugs, other therapies

    When Dr. Shehnaaz Suliman joined ReCode Therapeutics Inc. in December as CEO, she knew of the oversubscribed $80 million Series B round the Menlo Park company raised two months before. The Series B extension was co-led by Leaps by Bayer, the venture capital arm of German drug giant Bayer AG, and Matrix Capital Management affiliate AyurMaya with participation from Amgen Ventures. ReCode already plans to file an investigational drug application with the Food and Drug Administration — launching the process of clinical trials — in the fourth quarter for an experimental treatment of primary ciliary dyskinesia and in second-quarter 2023 against cystic fibrosis.

  • Investopedia

    A Look Into Foreign Direct Investment Trends

    Foreign direct investments play an important role as an indicator of a healthy economy in terms of economic growth and long-term capital movement.